Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Dare Bioscience
(NASDAQ:DARE)
Intraday
$0.30
0.014
[4.90%]
After-Hours
$0.30
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$0.30
0.014
[4.90%]
At close: Apr 25
$0.30
0
[0.00%]
PreMarket: 4:21AM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Dare Bioscience Stock (NASDAQ:DARE)
Dare Bioscience Stock (NASDAQ: DARE)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, April 24, 2024
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights
-
13 hours ago
Tuesday, April 23, 2024
Daré Bioscience To Receive $1M Installment Under Grant To Advance Development Of DARE-LARC1
Benzinga Newsdesk
-
1 day ago
Wednesday, April 17, 2024
Dare Bioscience shares are trading lower after Brookline Capital downgraded the stock from Buy to Hold.
Benzinga Newsdesk
-
Apr 17, 2024, 1:31PM
Brookline Capital Downgrades Dare Bioscience to Hold
Benzinga Newsdesk
-
Apr 17, 2024, 1:28PM
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga Insights
-
Apr 17, 2024, 12:31PM
Thursday, April 11, 2024
Daré Bioscience Announces Publication In Contraception Of Efficacy And Safety Findings From A Pre-Pivotal Postcoital Test Study Of Ovaprene: An Investigational Hormone-Free Monthly Intravaginal Contraceptive
Benzinga Newsdesk
-
Apr 11, 2024, 8:15AM
Monday, April 01, 2024
HC Wainwright & Co. Reiterates Buy on Dare Bioscience, Maintains $6 Price Target
Benzinga Newsdesk
-
Apr 1, 2024, 6:06AM
Thursday, March 28, 2024
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights
-
Mar 28, 2024, 4:31PM
Dare Bioscience Q4 EPS $(0.06) Beats $(0.10) Estimate, Sales $1.81M Beat $1.79M Estimate
Benzinga Newsdesk
-
Mar 28, 2024, 11:15AM
Recap: Dare Bioscience Q4 Earnings
Benzinga Insights
-
Mar 28, 2024, 10:25AM
Daré Bioscience Reported FY23 Revenue of $2.8M Vs $2.07M Est, EPS Loss of $(0.35) Vs $(0.38) Est, Cash Balance of $10.5M
Benzinga Newsdesk
-
Mar 28, 2024, 8:11AM
Earnings Scheduled For March 28, 2024
Benzinga Insights
-
Mar 28, 2024, 5:24AM
Wednesday, March 27, 2024
Dare Bioscience Earnings Preview
Benzinga Insights
-
Mar 27, 2024, 10:01AM
Tuesday, March 26, 2024
'Supreme Court Unlikely To Limit Access To Abortion Pill' - Washington Post
Benzinga Newsdesk
-
Mar 26, 2024, 12:01PM
Monday, March 04, 2024
'France becomes first country to explicitly enshrine abortion rights in constitution' -Washington Post Report
Benzinga Newsdesk
-
Mar 4, 2024, 12:53PM
Wednesday, February 21, 2024
First Lady Jill Biden Unveils $100M In Federal Funding To Support R&D - Watch Out for These Women Health Stocks
Vandana Singh
-
Feb 21, 2024, 12:24PM
Wednesday, January 31, 2024
Daré Bioscience Announces End-of-Phase 2 Meeting With FDA On Development Of Sildenafil Cream, 3.6%; Co. And FDA Aligned On Key Elements Of Phase 3 Program
Benzinga Newsdesk
-
Jan 31, 2024, 8:02AM
Friday, January 26, 2024
Daré Bioscience CFO Lisa Walters-Hoffert Retires
Benzinga Newsdesk
-
Jan 26, 2024, 4:33PM
Wednesday, January 17, 2024
Daré Bioscience Announces Grant From The Bill & Melinda Gates Foundation Of $750,000 To Fund Activities Related To Bacteria-Based Live Biotherapeutic Product Development
Benzinga Newsdesk
-
Jan 17, 2024, 8:18AM
Thursday, January 04, 2024
Daré Bioscience's DARE-LARC1 Platform Technology Achieves Proof-Of-Concept Device That Has Transformative Potential For Women's Health As Well As In Treating A Broad Range Of Diseases
Benzinga Newsdesk
-
Jan 4, 2024, 8:02AM
Tuesday, December 26, 2023
Daré Bioscience Secures $12M In Royalty-Backed Investment Structure; Daré Issued To The Investor A 5-Year Warrant To Purchase An Aggregate Of 5M Shares Of Daré's Common Stock At An Exercise Price Of $0.3467 Per Share
Happy Mohamed
-
Dec 26, 2023, 8:02AM
Wednesday, December 20, 2023
Daré Bioscience Highlights Efficacy Data From Treatment Candidate For Painful Menstruation
Vandana Singh
-
Dec 20, 2023, 12:34PM
Daré Bioscience Announces Topline Pharmacokinetic And Exploratory Efficacy Results From The DARE-PDM1 Phase 1 Clinical Study
Benzinga Newsdesk
-
Dec 20, 2023, 8:15AM
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights
-
Dec 20, 2023, 8:07AM
Wednesday, December 13, 2023
Daré Bioscience Announces Funding Award Notice Of $2M From National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development to Support DARE-PTB1 Phase 1 Human Study
Benzinga Newsdesk
-
Dec 13, 2023, 8:05AM
Thursday, December 07, 2023
FDA Gives Nod To Daré Bioscience's Trial Of Non-Hormonal Treatment For Dyspareunia, Seeks Additional Funding
Vandana Singh
-
Dec 7, 2023, 10:01AM
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights
-
Dec 7, 2023, 8:07AM
Daré Bioscience Announces FDA Clearance Of Investigational New Drug Application For DARE-VVA1
Benzinga Newsdesk
-
Dec 7, 2023, 8:01AM
Monday, December 04, 2023
Daré Bioscience Has Commenced Its Pivotal Phase 3 Clinical Study Of Ovaprene, An Investigational Hormone-free Monthly Intravaginal Contraceptive
Benzinga Newsdesk
-
Dec 4, 2023, 8:06AM
Monday, November 20, 2023
Daré Bioscience And Premier Research Have Extended Their Partnership Agreement To Continue Providing On An Exclusive Basis Contract Research Organization Services Within The US To Support The Clinical Development Of Daré's Reproductive Health Portfolio
Benzinga Newsdesk
-
Nov 20, 2023, 8:06AM
Friday, November 10, 2023
HC Wainwright & Co. Maintains Buy on Dare Bioscience, Lowers Price Target to $6
Benzinga Newsdesk
-
Nov 10, 2023, 7:59AM
Thursday, November 09, 2023
Dare Bioscience Q3 EPS $(0.09) Beats $(0.10) Estimate, Sales $1.00M Beat $430.00K Estimate, Cash Balance $13.9M
Benzinga Newsdesk
-
Nov 9, 2023, 8:04AM
Earnings Scheduled For November 9, 2023
Benzinga Insights
-
Nov 9, 2023, 6:52AM
Wednesday, November 08, 2023
Earnings Outlook For Dare Bioscience
Benzinga Insights
-
Nov 8, 2023, 1:01PM
Wednesday, November 01, 2023
Daré Bioscience's Additional Findings From Exploratory Phase 2B RESPOND Study Of Sildenafil Cream In Women With Sexual Arousal Disorder Achieves Statistical Significance, Clinically Meaningful Improvement In Co-primary Endpoint Assessing Arousal Sensation
Benzinga Newsdesk
-
Nov 1, 2023, 8:11AM
Monday, October 16, 2023
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Insights
-
Oct 16, 2023, 5:31PM
Dare Bioscience shares are trading higher after the company announced the achievement of its first commercial milestone under license agreement for XACIATO vaginal gel.
Benzinga Newsdesk
-
Oct 16, 2023, 11:59AM
Daré Bioscience Announces Achievement Of First Commercial Milestone Under License Agreement For XACIATO Vaginal Gel, 2%, FDA-Approved Treatment For Bacterial Vaginosis In Females 12 Years Or Older
Benzinga Newsdesk
-
Oct 16, 2023, 8:21AM
Thursday, September 21, 2023
Daré Bioscience Announces Grant Funding Installment To Support Further Development Of Novel Contraceptive Technology DARE-LARC1; Daré May Receive A Total Of Up To Approximately $49 Million To Support Nonclinical Development Of DARE-LARC1
Benzinga Newsdesk
-
Sep 21, 2023, 8:06AM
Wednesday, September 20, 2023
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights
-
Sep 20, 2023, 5:31PM
Monday, September 11, 2023
Stocks That Hit 52-Week Lows On Monday
Benzinga Insights
-
Sep 11, 2023, 1:38PM
Friday, September 08, 2023
Stocks That Hit 52-Week Lows On Friday
Benzinga Insights
-
Sep 8, 2023, 1:58PM
Wednesday, September 06, 2023
Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights
-
Sep 6, 2023, 2:43PM
Tuesday, September 05, 2023
Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights
-
Sep 5, 2023, 1:34PM
Wednesday, August 30, 2023
Daré Bioscience Announced $7M Registered Direct Offering Including The Purchase And Sale Of 10M Shares And Warrants To Purchase Up To 10M Shares
Benzinga Newsdesk
-
Aug 30, 2023, 8:09AM
Friday, August 11, 2023
HC Wainwright & Co. Reiterates Buy on Dare Bioscience, Maintains $7 Price Target
Benzinga Newsdesk
-
Aug 11, 2023, 8:27AM
Thursday, August 10, 2023
Dare Bioscience Q2 EPS $(0.10), Inline
Benzinga Newsdesk
-
Aug 10, 2023, 8:02AM
Earnings Scheduled For August 10, 2023
Benzinga Insights
-
Aug 10, 2023, 6:59AM
Wednesday, August 09, 2023
Earnings Outlook For Dare Bioscience
Benzinga Insights
-
Aug 9, 2023, 1:02PM
Daré Bioscience Announces Publication In The Journal Of The North American Menopause Society Of Efficacy Findings For the Treatment Of Menopausal Symptoms From A Phase 1/2 Clinical Trial Of DARE-HRT1 Intravaginal Rings
Benzinga Newsdesk
-
Aug 9, 2023, 8:24AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch